Memphasys Signs Agreement to Distribute Felix Fertility Device Across Middle East and North Africa

Memphasys (ASX: MEM) has granted Qatar-based company International Technical Legacy (ITL) exclusive commercial and distribution rights to its innovative Felix male fertility sperm preparation system.

The five-year deal applies to approximately 353 clinics across 15 countries across the Middle East and North Africa, which perform a cumulative 140,000 in vitro fertilisation (IVF) cycles per year.

Each new clinic will receive consoles free of charge, and ITL will actively promote the first-in-class technology to new IVF clinics to ensure rapid uptake across the region.

Minimum Cartridge Order

Under the terms of the agreement, ITL must place an initial minimum order for Felix cartridges valued at $325,000 once the product has received regulatory clearance.

After this initial order has been fulfilled, Memphasys and ITL will agree on pricing and annual minimum purchase obligations for the next three years of the agreement.

This will establish a scalable recurring revenue model consistent with Felix’s “razor-and-blade” consumables strategy, and provide scope for early upside if expansion across ITL’s MENA clinics occurs ahead of expectations.

CE Mark Application

Memphasys lodged a CE Mark application for Felix to European Union authorities in June and expects to receive approval within 12 months, unlocking commercialisation opportunities across key global markets.

The company also plans to streamline regulatory processes in India, Australia, the Middle East and multiple Asia-Pacific territories, enabling faster commercial rollout.

Submitting the application on schedule reinforces Memphasys’ commitment to converting scientific innovation into near-term revenue and scaling it into meaningful markets.

Commercialisation Strategy

Memphasys chief executive officer Dr David Ali said the ITL agreement was a major milestone in the company’s commercialisation strategy.

“ITL is the clear leader in IVF infrastructure and consumables in the Middle East and its established relationships with more than 350 clinics provides us with an immediate pathway to market,” he said.

“The initial binding order upon CE Mark approval provides near-term revenue certainty, while the scale of the opportunity and ITL’s clinical expertise underpin the potential for long-term recurring revenues.”

Flagship Device

Memphasys developed Felix as a flagship device for use in human assisted reproductive technology, to gently and efficiently separate high-quality sperm using a proprietary electrophoresis-based method.

The system reduces sperm preparation time to just six minutes, compared to conventional centrifuge-based methods which can take up to 30 minutes.

Memphasys is currently in deep engagement with global commercial partners including a distribution agreement with Vitrolife (in Japan, Canada and New Zealand), a letter of intent with HerAnova Lifesciences in China, and research and development sales in the United Arab Emirates.